Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20.68M | $210.0M | 12.22% | +2.68M | 2026-06-30 |
| ARCH Venture Management, LLC | 12.69M | $129.0M | 7.50% | -222.5K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.50M | $117.0M | 6.79% | +2.28M | 2026-06-30 |
| SB INVESTMENT ADVISERS (UK) LTD | 10.95M | $111.0M | 6.47% | -- | 2026-06-30 |
| STATE STREET CORP | 9.96M | $101.0M | 5.89% | +2.82M | 2026-06-30 |
| GSK plc | 8.55M | $87.0M | 5.05% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.39M | $65.0M | 3.78% | +1.01M | 2026-06-30 |
| Point72 Asset Management, L.P. | 5.67M | $57.0M | 3.35% | +3.71M | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.35M | $34.0M | 1.98% | +690.5K | 2026-06-30 |
| DIMENSIONAL FUND ADVISORS LP | 3.12M | $31.0M | 1.84% | +539.7K | 2026-06-30 |
